The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel | Anticancer Research
a Progression-free survival of 63 Japanese patients with... | Download Scientific Diagram
ASCO 2018: Cabazitaxel in mCRPC: Real-life Use, Effectiveness, Safety, and Quality of Life in the FUJI Cohort
Jevtana: new option for metastatic prostate cancer | MIMS online
Clinical Trial Results for JEVTANA® (cabazitaxel) Injection
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Kaplan-Meier estimates of the probability of overall survival (OS) and... | Download Scientific Diagram
Kaplan-Meier estimates of the probability of overall survival (OS) and... | Download Scientific Diagram
ESMO 2021: A Prospective Phase II Trial of Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors: The CABA-GCT Study
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Cabazitaxel shows a consistently greater survival benefit compared to mitoxantrone in patients with mCRPC | de Bono | Nowotwory. Journal of Oncology
Kaplan–Meier curves of overall survival by treatment group (TROPIC... | Download Scientific Diagram
Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC
Early serum and hematological variables recorded after 3 cycles of... | Download Scientific Diagram
Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study | Anticancer Research
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial - European Urology
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer | NEJM
1415-Prostate metastatic cabazitaxel three weekly and prednisolone | eviQ
Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance | BMC Cancer | Full Text
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology
